IL277575B2 - Antibodies for chelated radionuclides - Google Patents

Antibodies for chelated radionuclides

Info

Publication number
IL277575B2
IL277575B2 IL277575A IL27757520A IL277575B2 IL 277575 B2 IL277575 B2 IL 277575B2 IL 277575 A IL277575 A IL 277575A IL 27757520 A IL27757520 A IL 27757520A IL 277575 B2 IL277575 B2 IL 277575B2
Authority
IL
Israel
Prior art keywords
seq
antibody
amino acid
acid sequence
heavy chain
Prior art date
Application number
IL277575A
Other languages
English (en)
Hebrew (he)
Other versions
IL277575A (en
IL277575B1 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL277575A publication Critical patent/IL277575A/en
Publication of IL277575B1 publication Critical patent/IL277575B1/en
Publication of IL277575B2 publication Critical patent/IL277575B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
IL277575A 2018-04-16 2019-04-16 Antibodies for chelated radionuclides IL277575B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
PCT/EP2019/059856 WO2019201959A1 (en) 2018-04-16 2019-04-16 Antibodies for chelated radionuclides

Publications (3)

Publication Number Publication Date
IL277575A IL277575A (en) 2020-11-30
IL277575B1 IL277575B1 (en) 2025-07-01
IL277575B2 true IL277575B2 (en) 2025-11-01

Family

ID=66476592

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277575A IL277575B2 (en) 2018-04-16 2019-04-16 Antibodies for chelated radionuclides

Country Status (31)

Country Link
US (2) US20220389116A1 (enExample)
EP (2) EP3781200B1 (enExample)
JP (3) JP7475283B2 (enExample)
KR (1) KR102884852B1 (enExample)
CN (1) CN112261952A (enExample)
AR (1) AR115053A1 (enExample)
AU (1) AU2019254537B2 (enExample)
BR (1) BR112020021061A2 (enExample)
CA (1) CA3096338A1 (enExample)
CL (1) CL2020002680A1 (enExample)
CR (1) CR20200548A (enExample)
DK (1) DK3781200T3 (enExample)
ES (1) ES2985352T3 (enExample)
FI (1) FI3781200T3 (enExample)
HR (1) HRP20241013T1 (enExample)
HU (1) HUE067622T2 (enExample)
IL (1) IL277575B2 (enExample)
LT (1) LT3781200T (enExample)
MA (1) MA52545B1 (enExample)
MX (1) MX2020010954A (enExample)
MY (1) MY207044A (enExample)
PE (1) PE20210442A1 (enExample)
PL (1) PL3781200T3 (enExample)
PT (1) PT3781200T (enExample)
RS (1) RS65753B1 (enExample)
SG (1) SG11202010066TA (enExample)
SI (1) SI3781200T1 (enExample)
TW (1) TWI874314B (enExample)
UA (1) UA130541C2 (enExample)
WO (1) WO2019201959A1 (enExample)
ZA (1) ZA202006121B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CR20230076A (es) * 2020-07-10 2023-03-13 Hoffmann La Roche Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
CA3204291A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法
JP2024546810A (ja) 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド 多量体化が低減されているｓｃＦｖ及び抗体
WO2024099526A1 (en) 2022-11-08 2024-05-16 Y-Mabs Therapeutics, Inc. Bispecific antibody compounds
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam
WO2026082710A1 (en) 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Small molecule-inducible recombinant receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2017194438A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
ES2809598T3 (es) 2014-12-23 2021-03-04 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de superinfecciones bacterianas post-influenza
EP3253799B1 (en) * 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
PE20180484A1 (es) * 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
CN112638416A (zh) 2018-04-16 2021-04-09 奥兰诺医药公司 针对螯合的放射性核素的抗体和清除剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2017194438A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEAL SARAH ET AL,, COMPARATIVE EFFICACY AND TOXICITY OF LU-177-VS Y-90-THERANOSTIC ANTI-HER2/ANTI-DOTA(METAL) PRETARGETED RADIOIMMUNOTHERAPY (ANTI-HER2 DOT-APRIT) OF HER2-EXPRESSING BREAST CANCER XENOGRAFTS WITH CURATIVE INTENT., 1 May 2017 (2017-05-01) *
CHRISTIAN KLEIN ET AL,, THE USE OF CROSSMAB TECHNOLOGY FOR THE GENERATION OF BI- AND MULTISPECIFIC ANTIBODIES, 10 June 2016 (2016-06-10) *
DAMIAN J. GREEN ET AL,, COMPARATIVE ANALYSIS OF BISPECIFIC ANTIBODY AND STREPTAVIDIN-TARGETED RADIOIMMUNOTHERAPY FOR B-CELL CANCERS, 2 September 2016 (2016-09-02) *
LARSON STEVEN M ET AL,, RADIOIMMUNOTHERAPY OF HUMAN TUMOURS., 22 May 2015 (2015-05-22) *
YAZAKI ET AL,, HUMANIZATION OF THE ANTI-CEA T84.66 ANTIBODY BASED ON CRYSTAL STRUCTURE DATA, 1 January 2004 (2004-01-01) *
YAZAKI PAUL J ET AL,, A SERIES OF ANTI-CEA/ANTI-DOTA BISPECIFIC ANTIBODY FORMATS EVALUATED FOR PRE-TARGETING: COMPARISON OF TUMOR UPTAKE AND BLOOD CLEARANCE., 21 November 2012 (2012-11-21) *

Also Published As

Publication number Publication date
CL2020002680A1 (es) 2021-02-12
SI3781200T1 (sl) 2024-09-30
EP3781200B1 (en) 2024-05-29
ZA202006121B (en) 2025-05-28
JP2024056687A (ja) 2024-04-23
PE20210442A1 (es) 2021-03-08
EP3781200A1 (en) 2021-02-24
TW202011987A (zh) 2020-04-01
JP2026062683A (ja) 2026-04-10
HRP20241013T1 (hr) 2024-10-25
IL277575A (en) 2020-11-30
MA52545A (fr) 2021-02-24
HUE067622T2 (hu) 2024-10-28
CA3096338A1 (en) 2019-10-24
CR20200548A (es) 2021-01-20
JP2021520832A (ja) 2021-08-26
IL277575B1 (en) 2025-07-01
JP7475283B2 (ja) 2024-04-26
PT3781200T (pt) 2024-07-19
UA130541C2 (uk) 2026-03-18
SG11202010066TA (en) 2020-11-27
BR112020021061A2 (pt) 2021-02-17
CN112261952A (zh) 2021-01-22
US20220389116A1 (en) 2022-12-08
ES2985352T3 (es) 2024-11-05
MY207044A (en) 2025-01-27
TWI874314B (zh) 2025-03-01
AU2019254537A1 (en) 2020-10-29
AR115053A1 (es) 2020-11-25
FI3781200T3 (fi) 2024-07-31
EP4406607A3 (en) 2024-10-16
DK3781200T3 (da) 2024-08-05
AU2019254537B2 (en) 2025-06-19
WO2019201959A1 (en) 2019-10-24
KR102884852B1 (ko) 2025-11-14
US20260015436A1 (en) 2026-01-15
KR20210005885A (ko) 2021-01-15
PL3781200T3 (pl) 2024-09-16
RS65753B1 (sr) 2024-08-30
EP4406607A2 (en) 2024-07-31
LT3781200T (lt) 2024-08-12
MA52545B1 (fr) 2024-08-30
MX2020010954A (es) 2020-11-09

Similar Documents

Publication Publication Date Title
IL277575B2 (en) Antibodies for chelated radionuclides
JP2021520832A5 (enExample)
JP2024056687A5 (enExample)
JP2021503455A5 (enExample)
JP2023539245A5 (enExample)
JP2023538945A5 (enExample)
IL272747B1 (en) Bispecific antibodies 1 + 2
JP2021508469A5 (enExample)
JP2020508655A5 (enExample)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
FI3328893T3 (fi) Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja
JP2018522888A5 (enExample)
JP2017504578A5 (enExample)
NZ595687A (en) Anti-tnf-alpha antibodies and their uses
PE20230408A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
JP2022512234A5 (enExample)
IL279901B1 (en) Antibodies comprising a polypeptide inserted in framework 3 region
JP2025160226A5 (enExample)
JP2020502233A5 (enExample)
JP2022540610A5 (enExample)
JP2023520969A5 (enExample)
JP2023511376A5 (enExample)
JP2023549555A5 (enExample)
JP2021529524A5 (enExample)